Asset profile
Tenofovir disoproxil fumarate (Viread)
Small molecule
Evidence outlook
Approved: Chronic Hepatitis B
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
41 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 41 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Tenofovir Disoproxil Fumarate (Viread): this drug | Approved | Small molecule | HIV reverse transcriptase (RT) | ||
| Adefovir Dipivoxil (Hepsera) | Approved | Small molecule | — | ||
| Entecavir (Baraclude) | Approved | Small molecule | — | ||
| Hepatitis B Immune Globulin (HepaGam B) | Approved | Small molecule | — | ||
| Interferon Alfa-2b (Intron A) | Approved | — | Type I interferon receptor | ||
| Lamivudine (Epivir-HBV) | Approved | — | — | ||
| Peginterferon Alfa-2a (Pegasys) | Approved | — | Type I interferon receptor | ||
| Telbivudine (Tyzeka) | Approved | — | — | ||
| Tenofovir Alafenamide (Vemlidy) | Approved | Small molecule | — | ||
| Diluted I.V.-Hepabig inj(GC5103) | Phase 3 | Biologic (subtype unspecified) | — | ||
| Envafolimab | Phase 3 | Monoclonal antibody | PD-L1 | ||
| Hepalatide | Phase 3 | Peptide | NTCP | ||
| Human Hepatitis B Immunoglobulin (Hepatect®CP / Zutectra®) | Phase 3 | Small molecule | — | ||
| Tenofovir Amibufenamide (Hengmu) | Phase 3 | Small molecule | — | ||
| TQA3605 | Phase 3 | — | — | ||
| TVAX-008 | Phase 3 | — | — |
…and 26 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
2027 (4)
July 2027 (1)
What to watch
August 2027 (2)
September 2027 (1)
What to watch
2028 (5)
January 2028 (2)
June 2028 (1)
What to watch
September 2028 (1)
What to watch
November 2028 (1)
What to watch
2034 (1)
December 2034 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.